# Illumina, Inc.: Form 10-Q for the period ended Oct 1, 2023

- Company: [Illumina, Inc.](/companies/ilmn.md) (CIK 1110803)
- Form: 10-Q
- Filed: 2023-11-13
- Accepted by EDGAR: Nov 9, 2023, 18:30 ET
- Period: 2023-10-01
- Accession: 0001110803-23-000086
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1110803/000111080323000086/ilmn-20231001.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1110803/000111080323000086/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-10-01.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-07-03 to 2023-10-01 | $1.12bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2023-01-02 to 2023-10-01 | $3.38bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2023-07-03 to 2023-10-01 | $435.0m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2023-01-02 to 2023-10-01 | $1.31bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2023-07-03 to 2023-10-01 | $684.0m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2023-01-02 to 2023-10-01 | $2.07bn | us-gaap:GrossProfit |
| Research and development | 3 months, 2023-07-03 to 2023-10-01 | $315.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2023-01-02 to 2023-10-01 | $1.01bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2023-07-03 to 2023-10-01 | $303.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2023-01-02 to 2023-10-01 | $1.13bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2023-07-03 to 2023-10-01 | −$754.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2023-01-02 to 2023-10-01 | −$905.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-07-03 to 2023-10-01 | $19.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2023-01-02 to 2023-10-01 | $59.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-07-03 to 2023-10-01 | −$28.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2023-01-02 to 2023-10-01 | $36.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-07-03 to 2023-10-01 | −$754.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2023-01-02 to 2023-10-01 | −$986.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-07-03 to 2023-10-01 | −$4.77 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2023-01-02 to 2023-10-01 | −$6.23 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-07-03 to 2023-10-01 | −$4.77 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2023-01-02 to 2023-10-01 | −$6.23 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-07-03 to 2023-10-01 | 158,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2023-01-02 to 2023-10-01 | 158,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2023-01-02 to 2023-10-01 | $254.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2023-01-02 to 2023-10-01 | $144.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | at 2023-10-01 | $2.51bn | us-gaap:AssetsCurrent |
| Total assets | at 2023-10-01 | $10.12bn | us-gaap:Assets |
| Current liabilities | at 2023-10-01 | $1.48bn | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2023-10-01 | $5.90bn | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1110803/000111080323000086/ilmn-20231001.htm

Filed Nov 13, 2023.
Source: SEC EDGAR, the filing index for accession 0001110803-23-000086. Last ingested by Listed: Nov 14, 2026, 13:59 ET. No prices; not investment advice.
